Oral interferon-alpha lozenges: Completed Phase II enrollment

Vita's CytoPharm Inc. subsidiary completed enrollment of 165 patients in a double-blind, placebo-controlled, Taiwanese Phase II trial evaluating 500 and 1,500 units/day oral interferon-alpha lozenges...